Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved ...

Dawnzera is designed to inhibit plasma prekallikrein, a significant activator of the inflammatory mediators that cause acute HAE attacks. This 80mg dose of the medicine is self-administered through a ...

The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe ...

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

H.C. Wainwright raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $70 from $65 and keeps a Buy rating on the shares following FDA ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

Since 2008, the FDA has approved 11 treatments for a rare genetic condition called hereditary angioedema (HAE), three of ...

Piper Sandler raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $65 from $62 and keeps an Overweight rating on the shares ...

Ionis Pharmaceuticals rose 2.38% after hours following a planned stock sale by its chief scientific officer under a Rule 10b5-1 plan.

IONIS PHARMACEUTICALS INC WKN: A2ACMZISIN: US4622221004Ticker-Symbol: ISI Tradegate 18.08.25 | 16:58 37,590Euro +0,45 % +0,170 Branche Pharma Aktienmarkt NASDAQ Biotech 1-Jahres-Chart 5-Tage-Chart ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $60.2, a high ...